Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UJK0
UPID:
TSR3_HUMAN
Alternative names:
20S S rRNA accumulation protein 3 homolog
Alternative UPACC:
Q9UJK0; Q6PJT8
Background:
The 18S rRNA aminocarboxypropyltransferase, also known as 20S S rRNA accumulation protein 3 homolog, plays a crucial role in the modification of 18S rRNA. It catalyzes the aminocarboxypropyl transfer on pseudouridine at position 1248, marking the final step in the biosynthesis of the hypermodified nucleoside, N1-methyl-N3-(3-amino-3-carboxypropyl) pseudouridine, a modification conserved across eukaryotic 18S rRNA.
Therapeutic significance:
Understanding the role of 18S rRNA aminocarboxypropyltransferase could open doors to potential therapeutic strategies.